Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
amantadine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| amantadine hydrochloride | DRUG | - |
| oseltamivir phosphate | DRUG | - |
Inclusion Criteria: * Healthy male or female subjects aged 18 to 45 years, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests * Vital signs within the following ranges: * oral body temperature 35.0 - 37.5°C * sys...
Amantadine is a small molecule being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial evaluating its safety and pharmacokinetic effects. The drug is being developed by Novartis AG.
Amantadine is being developed by Novartis AG, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research on this small molecule drug.
Amantadine is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
Amantadine has been studied in one clinical trial, identified as NCT00416962. This Phase 1 study, titled 'Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine,' was completed in the United States with 18 healthy volunteers.
No, amantadine is not the same as oseltamivir. They are separate drugs that were studied together in a clinical trial. The trial NCT00416962 evaluated the safety and pharmacokinetic effects of oseltamivir alone or in combination with amantadine in healthy volunteers.